The global pharmaceutical continuous manufacturing market was valued at $393 million in 2018, and is projected to reach $855 million by 2026, registering a CAGR of 10.2% from 2019 to 2026. Continuous manufacturing is advanced manufacturing approach that is performed by employing end-to-end integration of manufacturing subprocesses with a significant level of control strategies.
The growth of the global pharmaceutical continuous manufacturing market is anticipated to be driven by increase in adoption of continuous manufacturing systems over existing drug manufacturing process, technological advancements in CM systems, and rise in awareness of continuous manufacturing systems in developing regions are anticipated to significantly boost the growth of the pharmaceutical continuous manufacturing market during the forecast period. Continuous pharmaceutical manufacturing system offers advantages such as reduced fluctuation in production, improved yields, lower cost of operation & equipment further augment the market growth.
Moreover, initiatives taken by the Food and drug Administration (FDA) for promoting the use of pharmaceutical continuous manufacturing systems and advantage of CM systems over the batch manufacturing are the major factors to boost the growth of pharmaceutical continuous manufacturing market. However, higher cost of pharmaceutical continuous manufacturing systems impede the market growth.
Moreover, the CM process is more time-efficient, reduces energy needs, helps to an increase productivity, and minimizes overall waste, which are expected to offer lucrative opportunity for the pharmaceutical continuous manufacturing market during the forecast period.
The global pharmaceutical continuous manufacturing market is segmented into product, application, end user, and region. On the basis of product, the market is classified into integrated continuous systems, semicontinuous systems, and control & software. By application, it is divided into final drug product manufacturing and API manufacturing. Depending on end user, it is categorized into pharmaceutical companies, contract manufacturing organizations, and others. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, and Rest of Europe), Asia-Pacific (China, Japan, India, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
KEY MARKET SEGMENTS
By Product
By Application Type
By End User
By Region
LIST OF KEY PLAYERS PROFILED IN THE REPORT
The growth of the global pharmaceutical continuous manufacturing market is anticipated to be driven by increase in adoption of continuous manufacturing systems over existing drug manufacturing process, technological advancements in CM systems, and rise in awareness of continuous manufacturing systems in developing regions are anticipated to significantly boost the growth of the pharmaceutical continuous manufacturing market during the forecast period. Continuous pharmaceutical manufacturing system offers advantages such as reduced fluctuation in production, improved yields, lower cost of operation & equipment further augment the market growth.
Moreover, initiatives taken by the Food and drug Administration (FDA) for promoting the use of pharmaceutical continuous manufacturing systems and advantage of CM systems over the batch manufacturing are the major factors to boost the growth of pharmaceutical continuous manufacturing market. However, higher cost of pharmaceutical continuous manufacturing systems impede the market growth.
Moreover, the CM process is more time-efficient, reduces energy needs, helps to an increase productivity, and minimizes overall waste, which are expected to offer lucrative opportunity for the pharmaceutical continuous manufacturing market during the forecast period.
The global pharmaceutical continuous manufacturing market is segmented into product, application, end user, and region. On the basis of product, the market is classified into integrated continuous systems, semicontinuous systems, and control & software. By application, it is divided into final drug product manufacturing and API manufacturing. Depending on end user, it is categorized into pharmaceutical companies, contract manufacturing organizations, and others. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, and Rest of Europe), Asia-Pacific (China, Japan, India, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
- A comprehensive analysis of four major regions is provided to determine the existing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Product
- Integrated Continuous Systems
- Semicontinuous Systems
- Control & Software
By Application Type
- Final Drug Product Manufacturing
- API Manufacturing
By End User
- Pharmaceutical Companies
- Contract Manufacturing Organizations
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
- Bosch Packaging Technology
- Coperion GmbH
- GEA Group AG
- Gebrüder Lödige Maschinenbau GmbH
- Glatt GmbH
- Hosokawa Micron Corporation
- Korsch AG
- L.B. Bohle Maschinen + Verfahren GmbH
- Munson Machinery Company, Inc.
- Thermo Fisher Scientific Inc.
Table of Contents
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Overview
Chapter 4: Pharmaceutical Continuous Manufacturing Market, By Product
Chapter 5: Pharmaceutical Continuous Manufacturing Market, By Application
Chapter 6: Pharmaceutical Continuous Manufacturing Market, By End User
Chapter 7: Pharmaceutical Continuous Manufacturing Market, By Region
Chapter 8: Company Profiles
Executive Summary
According to the report titled, 'Pharmaceutical Continuous Manufacturing Market, by Product, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2019-2026', the global pharmaceutical continuous manufacturing market was valued at $393 million in 2018, and is expected to reach $855 million by 2026, growing at a CAGR of 10.2% from 2019 to 2026.Continuous manufacturing is an advanced manufacturing approach to provide pharmaceutical products with enhanced quality, improved yield, reduced cost within shorter time period. Pharmaceutical continuous manufacturing market is expected to witness significant grow growth during the forecast period, due to an increase in adoption of continuous manufacturing systems over the existing drug manufacturing process, technological advancements, initiatives taken by the Food and drug Administration (FDA) for promoting the use of pharmaceutical continuous manufacturing for modernizing pharmaceutical manufacturing, and advantage over the batch manufacturing. However, higher cost of pharmaceutical continuous manufacturing systems restrain the market growth.
Depending on product, the market is categorized into integrated continuous systems, semi-continuous systems, and control & software. Presently, the integrated continuous systems dominates the global market, and is anticipated to continue this trend over the forecast period. This is attributed to rise in adoption of integrated continuous manufacturing (ICM) systems, technological advancements, and rise in preference for ICM systems as compared to the existing drug manufacturing systems.
By application, the global pharmaceutical continuous manufacturing market size is segregated into final drug product manufacturing and API manufacturing. At present, the final drug product manufacturing segment is the major revenue generator, and is anticipated to experience significant growth during the forecast period due to a surge in adoption of continuous manufacturing systems in pharmaceutical companies to improve yield, reduced cost of pharmaceutical substances, and to develop drugs within shorter time.
Key Findings of the Pharmaceutical Continuous Manufacturing Market:
On the basis of product, the integrated continuous systems segment held more than 60% share in the global market in 2018.
By end user, the pharmaceutical companies segment exhibits fastest growth, and is expected to grow at a CAGR of 10.7% from 2019 to 2026.
Depending on application, the final drug product manufacturing segment held largest market share in 2018, and is expected to remain dominant throughout the forecast period.
Region wise, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 11.5% during the forecast period.
North America accounted for approximately one-half of the global pharmaceutical continuous manufacturing market share in 2018, and is expected to remain dominant throughout the forecast period. This was attributed to higher adoption of pharmaceutical continuous manufacturing systems, increase in presence of pharmaceutical companies, availability of well-developed healthcare infrastructure, wide availability of advanced pharmaceutical continuous manufacturing systems, and supportive government policies for adoption of continuous manufacturing systems. However, Asia-Pacific is expected to experience fastest pharmaceutical continuous manufacturing market growth during the forecast period, majorly due to an increase in adoption of pharmaceutical continuous manufacturing systems.
Companies Mentioned
- Bosch Packaging Technology
- Coperion GmbH
- GEA Group AG
- Gebrüder Lödige Maschinenbau GmbH
- Glatt GmbH
- Hosokawa Micron Corporation
- Korsch AG
- L.B. Bohle Maschinen + Verfahren GmbH
- Munson Machinery Company Inc.
- Thermo Fisher Scient
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 245 |
| Published | December 2019 |
| Forecast Period | 2018 - 2026 |
| Estimated Market Value ( USD | $ 393 million |
| Forecasted Market Value ( USD | $ 855 million |
| Compound Annual Growth Rate | 10.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
